Nautilus Biotechnology, Inc. (NAUT) Cash Flow Statement
Nautilus Biotechnology, Inc. (NAUT) generated -$50.2M of operating cash flow over the twelve months to 2026-06-30, spent $1.6M on capital expenditure and had free cash flow of -$51.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAUTNautilus Biotechnology, Inc.Follow NAUT — free
—
Price chart with a free account
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -39.2 | -45.8 | -51.7 | -59.1 | -50.7 | -50.2 | |
| Capital expenditure | 2.3 | 2.3 | 2.4 | 2.1 | 1.3 | -1.6 | |
| Free cash flow | -41.5 | -48.1 | -54.2 | -61.3 | -52.0 | -51.9 | |
| Stock-based compensation | 7.9 | 10.4 | 12.1 | 12.7 | 6.8 | — |
USD millions · SEC XBRL
Nautilus Biotechnology, Inc. — questions
- What is Nautilus Biotechnology, Inc.'s operating cash flow?
- -$50.2M over the twelve months to 2026-06-30.
- How much does Nautilus Biotechnology, Inc. spend on capital expenditure?
- $1.6M over the twelve months to 2026-06-30.
- What is Nautilus Biotechnology, Inc.'s free cash flow?
- -$51.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.